<DOC>
	<DOC>NCT02636101</DOC>
	<brief_summary>This study aims to describe the patient population treated and the real-life patients' experiences with Xamiol®gel in the long term, up to 52 weeks management of body psoriasis vulgaris in Russia. The result will increase the knowledge on Xamiol®gel enabling dermatologists and patients to optimize its use in the long term management of psoriasis.</brief_summary>
	<brief_title>Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Psoriasis vulgaris on body Patients planned to receive topical treatment on the body with calcipotriol/betamethasone gel Written informed consent No or very mild symptoms of psoriasis vulgaris on the body at study start Any ongoing treatments at study start with topical steroids, salicylic acid or its combination Other topical treatment for body psoriasis Pregnancy or planned pregnancy within treatment period Contraindications according to prescribing information.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>